A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir. (27th October 2022)

• Record Type: Journal Article
• Authors: Ramirez-Sanchez, Claudia; Kozuch, Jade; Shah, Mita M; Berumen, Jennifer; Mekeel, Kristin; Schnickel, Gabriel; Taremi, Mahnaz; Golts, Eugene; Afshar, Kamyar; Adler, Eric; Pretorius, Victor; Aslam, Saima
• Is Part Of: Open forum infectious diseases. Volume 9:Number 11(2022)
• Publication Date: 2022-10-27
• Subjects: DAA -- direct-acting antiviral -- donor-derived infection -- glecaprevir/pibrentasvir -- prophylaxis -- HCV; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac550
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks. Abstract : A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.